Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation
- PMID: 20232141
- DOI: 10.1007/s10549-010-0817-z
Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation
Abstract
Germline mutations in BRCA1 and BRCA2 increase the risk for developing breast and ovarian cancer. Previously, the techniques available allowed only for the identification of small genomic alterations, but the dawn of new technology now allows for the rapid detection of large genomic rearrangements (LGRs). LGRs in BRCA1 are responsible for between 0 and 27% of all BRCA1 disease-causing mutations identified in numerous populations. Such alterations are far less common in the BRCA2 gene. To determine the impact of BRCA1 and BRCA2 LGRs in South Africa, 52 hereditary breast and/or ovarian South African families (36 were Afrikaners) were screened for BRCA1 and BRCA2 LGRs using multiplex ligation-dependent probe amplification. These patients were previously shown to be BRCA1 and BRCA2 small mutation negative. One LGR was detected in BRCA1 in a South African family with Greek ancestry. This is a novel deletion of both exons 23 and 24 (NG_005905.2:g.169527_180579del). This first study of BRCA rearrangements in South Africa reveals that LGRs comprise ~3% of identified BRCA1 mutations, a low rate in comparison to other populations. In addition, we have reviewed all 98 previously characterized BRCA1/2 LGRs and re-named them according to the recommended HGVS nomenclature, using the recently released RefSeqGene records, NG_005905.2 and NG_012772.1 for BRCA1 and BRCA2. A standardized resource is now provided which will assist researchers in determining whether their LGRs are novel. Furthermore, we have clarified some of the previously misunderstood rules of nomenclature, which will make uniform reporting of BRCA1/2 easier in the future.
Comment in
-
Comments on: Sluiter MD and van Rensburg EJ, Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation.Breast Cancer Res Treat. 2010 Nov;124(1):295-6. doi: 10.1007/s10549-010-1111-9. Epub 2010 Aug 13. Breast Cancer Res Treat. 2010. PMID: 20706784 No abstract available.
Similar articles
-
Screening for genomic rearrangements in BRCA1 and BRCA2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene.Breast Cancer Res Treat. 2010 Nov;124(2):337-47. doi: 10.1007/s10549-010-0745-y. Epub 2010 Feb 5. Breast Cancer Res Treat. 2010. PMID: 20135348
-
MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single early-onset cases.Hum Mutat. 2008 Jul;29(7):948-58. doi: 10.1002/humu.20723. Hum Mutat. 2008. PMID: 18431737
-
Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer.Breast Cancer Res Treat. 2007 May;103(1):103-7. doi: 10.1007/s10549-006-9376-8. Epub 2006 Oct 25. Breast Cancer Res Treat. 2007. PMID: 17063271
-
Genomic rearrangements in the BRCA1 and BRCA2 genes.Hum Mutat. 2005 May;25(5):415-22. doi: 10.1002/humu.20169. Hum Mutat. 2005. PMID: 15832305 Review.
-
Pitfalls and caveats in BRCA sequencing.Ultrastruct Pathol. 2006 May-Jun;30(3):229-35. doi: 10.1080/01913120500521281. Ultrastruct Pathol. 2006. PMID: 16825125 Review.
Cited by
-
Gender-Specific Genetic Predisposition to Breast Cancer: BRCA Genes and Beyond.Cancers (Basel). 2024 Jan 30;16(3):579. doi: 10.3390/cancers16030579. Cancers (Basel). 2024. PMID: 38339330 Free PMC article. Review.
-
A MALDI-TOF mass spectrometry-based method for detection of copy number variations in BRCA1 and BRCA2 genes.Front Mol Biosci. 2024 Jan 11;10:1301652. doi: 10.3389/fmolb.2023.1301652. eCollection 2023. Front Mol Biosci. 2024. PMID: 38274092 Free PMC article.
-
Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types.Clin Cancer Res. 2024 Feb 16;30(4):836-848. doi: 10.1158/1078-0432.CCR-23-2693. Clin Cancer Res. 2024. PMID: 38060240 Free PMC article.
-
Case Report: Clinical benefit from multi-target tyrosine kinase inhibitor and PARP inhibitor in a patient with cancer of unknown primary with BRCA1 large genomic rearrangement.Front Pharmacol. 2023 Jan 23;14:997760. doi: 10.3389/fphar.2023.997760. eCollection 2023. Front Pharmacol. 2023. PMID: 36755949 Free PMC article.
-
Copy Number Variants Are Ovarian Cancer Risk Alleles at Known and Novel Risk Loci.J Natl Cancer Inst. 2022 Nov 14;114(11):1533-1544. doi: 10.1093/jnci/djac160. J Natl Cancer Inst. 2022. PMID: 36210504 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
